UNSPSC 51141508: Ethosuximide

This classification denotes an anticonvulsant agent with the molecular formula C7H11NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5SEH9X1D1D, chemically known as 2,5-pyrrolidinedione, 3-ethyl-3-methyl- but generally known as ethosuximide, which bears US NIH Compound Identifier 3291. European Medicines Agency schedules Ethosuximide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07282MIG.

UNSPSC 51141508 Ethosuximide is a Commodity code for a specific anticonvulsant pharmaceutical product, but the recent state and local solicitation activity under this code does not reflect pharmaceutical procurement aligned with the code's nominal scope. Seminole County, Florida posted an IFB in June 2026 seeking Naloxone and Safe Drug Deactivation Systems — emergency opioid-reversal and drug-disposal equipment — which fall outside the seizure-medication category the code describes. The mismatch suggests either a tagging error in the county's procurement system or a broader catch-all application of the code to pharmaceutical and health-related goods that state and local offices may not be applying with strict UNSPSC taxonomy discipline.

The single recent opportunity on record is Seminole County, Florida's IFB60459723LAS, posted June 30, 2026, with a response deadline of July 26, 2023 (note the date discrepancy in the source), seeking annual delivery of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems on a quarterly basis to the Seminole County Community Health Building in Sanford, Florida. The contract carries a two-year initial term with an optional one-year renewal, fixed-fee pricing, and standard compliance requirements including E-Verify and workers' compensation insurance. Potential FEMA funding introduces federal environmental and regulatory compliance obligations. The code shows limited recent activity; no other jurisdictions or states appear in the recent-opportunities record, and the single posting's product scope diverges substantially from the code's intended pharmaceutical classification. Business development professionals evaluating this code should verify whether their pharmaceutical or medical-equipment offering aligns with how state and local procurement offices are actually tagging opportunities — taxonomy drift at the commodity tier can create false positives in opportunity searches.